Cargando…

Renin profiling predicts neurohormonal response to sacubitril/valsartan

AIMS: Clinical trials and observational cohorts show that beneficial effects of sacubitril/valsartan are less strong in an appreciable proportion of patients with heart failure with reduced ejection fraction (HFrEF). Lower blood pressure and impaired renal function predict suboptimal sacubitril/vals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vergaro, Giuseppe, Sciarrone, Paolo, Prontera, Concetta, Masotti, Silvia, Musetti, Veronica, Valleggi, Alessandro, Giannoni, Alberto, Senni, Michele, Emdin, Michele, Passino, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835599/ https://www.ncbi.nlm.nih.gov/pubmed/33216460 http://dx.doi.org/10.1002/ehf2.13085

Ejemplares similares

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2019)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2023)

Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis
por: Pucci, Angela, et al.
Publicado: (2021)

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
por: Borrelli, Chiara, et al.
Publicado: (2019)

Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure
por: Gentile, Francesco, et al.
Publicado: (2022)

Differences in family caregiver experiences and expectations of end-of-life heart failure care across providers and settings: a systematic literature review
por: Valleggi, Alessandro, et al.
Publicado: (2023)

Novel Drug Targets for Central Apneas in Heart Failure: On the Road
por: Borrelli, Chiara, et al.
Publicado: (2021)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
por: Cacciatore, Francesco, et al.
Publicado: (2020)

Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
por: Fabiani, Iacopo, et al.
Publicado: (2023)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril‐Valsartan: A Multicenter Echocardiographic Registry
por: Mandoli, Giulia Elena, et al.
Publicado: (2022)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
por: Tolomeo, Paolo, et al.
Publicado: (2022)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
por: Vergaro, Giuseppe, et al.
Publicado: (2021)

Rationale and design of TRANSITION: a randomized trial of pre‐discharge vs. post‐discharge initiation of sacubitril/valsartan
por: Pascual‐Figal, Domingo, et al.
Publicado: (2017)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure
por: Witte, Klaus K., et al.
Publicado: (2022)

Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2020)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Biomarkers for the diagnosis and management of heart failure
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
por: Lee, Seonhwa, et al.
Publicado: (2020)

The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non‐responders: a retrospective analysis
por: Chun, Kyeong‐Hyeon, et al.
Publicado: (2020)

Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry
por: Khariton, Yevgeniy, et al.
Publicado: (2020)

Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
por: Norberg, Helena, et al.
Publicado: (2019)

Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis
por: Giovinazzo, Stefano, et al.
Publicado: (2021)

Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension
por: Iwashima, Yoshio, et al.
Publicado: (2023)

Renal protection in chronic heart failure: focus on sacubitril/valsartan
por: Pontremoli, Roberto, et al.
Publicado: (2021)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register
por: Pastore, Maria Concetta, et al.
Publicado: (2021)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Valsartan/Sacubitril in heart failure and hypotension: how, when and why
por: Scardovi, Angela Beatrice, et al.
Publicado: (2019)

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF
por: Mogensen, Ulrik M., et al.
Publicado: (2017)

Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan
por: Correale, Michele, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7u95s3jvta1aa98v5mk3kmqijr